Objective To investigate the effect of ulinastatin in adjuvant treatment of ventilator-associated pneumonia(VAP)and preliminary clinical efficacy of the therapy mechanism.Methods 76 patients with ventilator-associated pneumonia from January 2015 to February 2016 in Qingyuan People's Hospital of Zhejiang Province were selected and randomly divided into control group and observation group,38 cases in each group.Two groups were given mechanical ventilation,phlegm,anti infection,rehydration,nutritional support and other conventional treatment,the observation group on the basis of routine treatment for ulinastatin adjuvant therapy,comparison of two groups of treatment,the simultaneous determination of serum interleukin-6(IL-6),C-reactive protein(CRP)and procalcitonin(PCT)and tumor necrosis factor alpha(TNF-alpha)levels were measured before and after treatment.Results The total efficiency of the observation group was 94.74％,significantly higher than the control group 78.95％,the difference was statistically significant(P<0.05),the two groups after treatment of serum CRP and PCT levels were decreased significantly compared with before treatment,the observation group after treatment,serum CRP and PCT levels were(45.19+5.79)mg/L and(1.08+0.36)μg/L was significantly lower than that before treatment and control group after treatment,the difference was statistically significant(P<0.05),the two groups after treatment of serum IL-6 and TNF-α levels were decreased significantly compared with before treatment,the observation group after treatment,serum IL-6 and TNF-α levels were(165.29+19.23)pm/mL and(1.16+0.25)pm/mL,was significantly lower than that before treatment and control group after treatment,the difference was statistically significant(P<0.05).Conclusion The inflammatory reaction in patients with ventilator-associated pneumonia ulinastatin can effectively reduce auxiliary patients,reduce inflammatory factors on lung injury,can alleviate the disease progression and to improve its prognosis.

Objective To explore the effects of the 4C continuing care model on the living ability and neurological function in patients with cerebral apoplexy during the rehabilitation period.Methods Totally 112 patients with cerebral apoplexy admitted in No.3 Ward of Qiongyuan People's Hospital from July 2014 to July 2016 and divided into the observation group (n=56) and the control group (n=56). Patients in the control group received conventional nursing care, while patients in the observation group received 4C continuing care. The patients' living ability, limb movement function and neurological function 1, 6 and 12 month before and after intervention were recorded and compared between the two groups.Results There was no statistical difference in the scores of living ability and neurological function between the two groups before intervention (P>0.05), However, there was statistical difference in the scores of living ability and neurological function between the two groups 1, 6 and 12 month after intervention (P<0.05). There was no statistical difference in the scores of limb movement function between the two groups before intervention (P>0.05). However, there was statistical difference in the scores of limb movement function between the two groups 6 month and 12 month after intervention (P<0.05).Conclusions The 4C continuing care model can effectively enhance the living ability and neurological function recovery in patients with cerebral apoplexy during the rehabilitation period.